TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30368658

Group type: COMPARATOR
Intervention: Tylerdipine 5-30 mg (SAD study)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tylerdipine 10 or 20 mg (MAD study)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (SAD study)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (MAD study)
Number of subjects: 88
Study: 28664722

Group type: EXPERIMENTAL
Intervention: Drug consumption among adolescents
Number of subjects: 17331

Group type: EXPERIMENTAL
Intervention: Designer drug consumption
Number of subjects: 17331

Group type: EXPERIMENTAL
Intervention: Knowledge about designer drugs
Number of subjects: 17331
Study: 26407095

Group type: EXPERIMENTAL
Intervention: Krill oil (2 g/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23371457

Group type: EXPERIMENTAL
Intervention: Jitongning Capsule
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 120
Study: 21338506

Group type: EXPERIMENTAL
Intervention: Preventure intervention consisting of two 90 minute group sessions provided by a qualified counsellor and a co-facilitator.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition receiving standard substance use education sessions as per the Dutch national curriculum.
Number of subjects: 0
Study: 18978640

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Symptom diary control
Number of subjects: 53
Study: 17679661

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention provided by nurse home visitors (environmental allergen and tobacco smoke reduction, illness management) for 12 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study: 15042388

Group type: EXPERIMENTAL
Intervention: EECP therapy with 5000 IU heparin pretreatment (H group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional EECP therapy (C group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EECP therapy with heparin pretreatment (H group)
Number of subjects: 18
Study: 11890513

Group type: EXPERIMENTAL
Intervention: Creative-dynamic image synthesis
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 10923530

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 105
Study: 8166475

Group type: EXPERIMENTAL
Intervention: Cis-platinum or carboplatin containing regimens
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Induction regimens (Etoposide (VP-16) and Teniposide (VM-26))
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Control arm (alternating regimen)
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Overall treatment protocols
Number of subjects: 1527
Study: 2844044

Group type: EXPERIMENTAL
Intervention: Rubber band ligation (RBL) + unprocessed bran (twice-daily intake for 18 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL) alone
Number of subjects: 92
Study: 29573212

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 3456

Group type: EXPERIMENTAL
Intervention: General medication use
Number of subjects: 3456

Group type: EXPERIMENTAL
Intervention: Medication use by age
Number of subjects: 3456

Group type: EXPERIMENTAL
Intervention: Salbutamol use by age
Number of subjects: 3456

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 3456
Study: 28707771

Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone daily from 18 to 34 weeks gestation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo ovule daily from 18 to 34 weeks gestation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 26589142

Group type: EXPERIMENTAL
Intervention: Pre-warmed SLIPA (37 °C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Room temperature SLIPA
Number of subjects: 90
Study: 24408336

Group type: EXPERIMENTAL
Intervention: 100 mg caffeine tablet
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 21176950

Group type: EXPERIMENTAL
Intervention: 440 mg albendazole and 40 mg/kg praziquantel
Number of subjects: 2507

Group type: EXPERIMENTAL
Intervention: 440 mg albendazole
Number of subjects: 2507

Group type: COMPARATOR
Intervention: 40 mg/kg praziquantel
Number of subjects: 2507
Study: 17909085

Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 17165280

Group type: EXPERIMENTAL
Intervention: Leukotriene modifier drugs
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Leukotriene modifier drugs in combination with systemic corticosteroids
Number of subjects: 676
Study: 14763200

Group type: EXPERIMENTAL
Intervention: One insertion of quinacrine pellets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Two insertions of quinacrine pellets
Number of subjects: 100
Study: 11068974

Group type: COMPARATOR
Intervention: TNS + placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (20 mg)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (40 mg)
Number of subjects: 224

Group type: COMPARATOR
Intervention: TNS + placebo (compliant participants)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (20 mg) (compliant participants)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (40 mg) (compliant participants)
Number of subjects: 224
Study: 8616547

Group type: EXPERIMENTAL
Intervention: Once weekly follow-up of pulmonary rehabilitation after home rehabilitation (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Once monthly follow-up of pulmonary rehabilitation after home rehabilitation (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No rehabilitation at all (Group C)
Number of subjects: 36
Study: 1424417

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ketorolac by titration
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ketorolac by bolus injection
Number of subjects: 92
Study: 3916836

Group type: EXPERIMENTAL
Intervention: liposteroid (2.5 mg of dexamethasone)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Decadron (3.3 mg of dexamethasone)
Number of subjects: 138
Study: 31467447

Group type: EXPERIMENTAL
Intervention: Rapid genome sequencing (GS)
Number of subjects: 23
Study: 27593706

Group type: EXPERIMENTAL
Intervention: Anti-reflux surgery (ARS)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Omeprazole (OME) 20-60 mg daily
Number of subjects: 245

Group type: COMPARATOR
Intervention: Both ARS and OME
Number of subjects: 245
Study: 25665607

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study: 22900530

Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic handrim wheelchair exercise (30-40% HRR) on a treadmill, 16 weeks, 2 times per week, 30 min per session
Number of subjects: 40
Study: 20647241

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP)
Number of subjects: 82
Study: 19782791

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: EuroQol Visual Analog Scale (VAS)
Number of subjects: 2331
Study: 17185206

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-yield nicotine cigarettes
Number of subjects: 35
Study: 15342613

Group type: EXPERIMENTAL
Intervention: 60 mg etoricoxib alone and following daily doses of 400 mg ketoconazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60 mg etoricoxib alone and following daily doses of 600 mg rifampin
Number of subjects: 24

Group type: COMPARATOR
Intervention: 120 mg etoricoxib once daily for 11 days
Number of subjects: 24
Study: 11727884

Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory (MCMI-II)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Structured Clinical Interview for DSM-III-R (SCID-II)
Number of subjects: 275
Study: 9737283

Group type: EXPERIMENTAL
Intervention: K4 (n=103)
Number of subjects: 220

Group type: COMPARATOR
Intervention: K5 (n=117)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: K4 (n=103) and K5 (n=117)
Number of subjects: 220
Study: 8074755

Group type: EXPERIMENTAL
Intervention: Albendazole (three 400‐mg doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2899357

Group type: EXPERIMENTAL
Intervention: Intranasal application of local anesthetic (bupivacaine or cocaine)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo control (saline)
Number of subjects: 17
Study: 29797800

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention alongside CPAP treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPAP treatment
Number of subjects: 0
Study: 26861639

Group type: EXPERIMENTAL
Intervention: CPAP at 5, 10, 20, and 30 hPa during CPR with various ventilators (Evita® V500, Medumat® Transport, Oxylator® EMX, Oxylog® 2000, Oxylog® 3000, Primus®, Servo®-i, Wenoll® diver rescue system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled ventilation CPR (as reported in literature)
Number of subjects: 0
Study: 25180908

Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) women
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) men
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) victims
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Severe mental illness (SMI) female victims
Number of subjects: 303

Group type: COMPARATOR
Intervention: General population women (control)
Number of subjects: 303

Group type: COMPARATOR
Intervention: General population men (control)
Number of subjects: 303

Group type: COMPARATOR
Intervention: General population victims (control)
Number of subjects: 303

Group type: COMPARATOR
Intervention: General population female victims (control)
Number of subjects: 303
Study: 22588361

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (flour capsule)
Number of subjects: 16
Study: 20634084

Group type: EXPERIMENTAL
Intervention: Topical application of autologous platelet-rich plasma
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard surgical leg wound closure and care (Control)
Number of subjects: 140
Study: 19070268

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg/kg/min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg/kg/min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0 microg/kg/min remifentanil)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All remifentanil groups
Number of subjects: 60
Study: 16652216

Group type: EXPERIMENTAL
Intervention: Hiberix and Infanrix‐DTPa (primary vaccination)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hiberix (booster dose)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hiberix and Infanrix‐DTPa (booster dose)
Number of subjects: 61
Study: 12589450

Group type: EXPERIMENTAL
Intervention: Symbolically cued movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directly cued movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed cuing (one directly cued, one symbolically cued)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compatible trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incompatible trials
Number of subjects: 0
Study: 10853207

Group type: COMPARATOR
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg plus dexamethasone 8 mg intravenously
Number of subjects: 130
Study: 9483021

Group type: EXPERIMENTAL
Intervention: Experimental intervention (dyadic support from former patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 55
Study: 8339858

Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg per day for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3522040

Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml
Number of subjects: 49

Group type: COMPARATOR
Intervention: metrizamide 240 mg I/ml
Number of subjects: 49
Study: 29234966

Group type: EXPERIMENTAL
Intervention: Collaborative multidisciplinary program for antibiotic prophylaxis
Number of subjects: 0
Study: 26992038

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX), n = 15, 24 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sedentary control (SED), n = 7, 24 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sedentary control (SED)
Number of subjects: 22
Study: 24786013

Group type: EXPERIMENTAL
Intervention: Orally soluble film (OSF) of 50 mg sildenafil
Number of subjects: 48

Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) of 50 mg sildenafil
Number of subjects: 48
Study: 22858078

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided management
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) management
Number of subjects: 151
Study: 20376520

Group type: EXPERIMENTAL
Intervention: MIPAS-Family
Number of subjects: 34

Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 34
Study: 18334811

Group type: EXPERIMENTAL
Intervention: Iscador M 5 mg spezial (IM spez)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (without mistletoe)
Number of subjects: 33
Study: 15806403

Group type: EXPERIMENTAL
Intervention: Polytraumatized children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polytraumatized adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polytraumatized children and adults
Number of subjects: 0
Study: 12902441

Group type: EXPERIMENTAL
Intervention: Paclitaxel, etoposide, and carboplatin (experimental arm)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Carboplatin, etoposide, and vincristine (standard arm)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 614
Study: 10078556

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 IU H-Insulin 100 Hoechst)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle (2.7 mg/ml m-Cresol)
Number of subjects: 18
Study: 7851587

Group type: EXPERIMENTAL
Intervention: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with elevated LH (> 35 mIU/mL)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with non-elevated LH (< 35 mIU/mL)
Number of subjects: 203
Study: 2184694

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.1 mg/kg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: piritramide 0.1 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 7387140

Group type: EXPERIMENTAL
Intervention: Netilmicin 1.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin 1.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netilmicin 2.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin 2.5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 30879607

Group type: EXPERIMENTAL
Intervention: Music group (n = 53)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Video game group (n = 56)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (n = 51)
Number of subjects: 160
Study: 28634972

Group type: EXPERIMENTAL
Intervention: 5-day treatment course with prednisone
Number of subjects: 311

Group type: COMPARATOR
Intervention: 14-day treatment course with prednisone
Number of subjects: 311
Study: 25889796

Group type: EXPERIMENTAL
Intervention: Personal Learning Plan (PLP) supported by an induction meeting
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no PLP or induction meeting)
Number of subjects: 143
Study: 23410849

Group type: EXPERIMENTAL
Intervention: 10-minute brief intervention
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 50-minute brief intervention
Number of subjects: 278

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 278
Study: 21803519

Group type: EXPERIMENTAL
Intervention: Basilic vein transposition (BBAVF)
Number of subjects: 57

Group type: COMPARATOR
Intervention: AV graft (AVG)
Number of subjects: 57
Study: 19118913

Group type: EXPERIMENTAL
Intervention: Vildagliptin 10mg bid
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25mg bid
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg bid
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 17551890

Group type: EXPERIMENTAL
Intervention: COPD case management protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 50
Study: 15626162

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 2 Hz
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 100 Hz
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at alternating frequency of 2 Hz and 100 Hz (2/100 Hz)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 2/100 Hz
Number of subjects: 34
Study: 15516630

Group type: EXPERIMENTAL
Intervention: Traveling to an endemic area 8-14 days before disease onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traveling 1-7, 15-21, or 22-30 days before disease onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of protection against mosquitoes
Number of subjects: 0
Study: 9852387

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - 2 mg estradiol (E2) for 12 days, followed by 2 mg E2 and 1 mg norethisterone acetate for 10 days, then 1 mg E2 for 6 days, cyclically during 6 months.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for the first 3 months, followed by the same HRT as the first group for the last 3 months.
Number of subjects: 50
Study: 8770316

Group type: EXPERIMENTAL
Intervention: L-arginine (16 g i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2287058

Group type: EXPERIMENTAL
Intervention: BMY-28100 (750 mg daily, divided into 3 administrations for at least 14 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: CCL (cefaclor, 1,500 mg daily, divided into 3 administrations for at least 14 days)
Number of subjects: 172
Study: 6169509

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (20% benzocaine)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31477676

Group type: EXPERIMENTAL
Intervention: Health literacy self-management intervention (7 sessions over 5 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Health literacy self-management intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 27557833

Group type: EXPERIMENTAL
Intervention: Rolapitant 180 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26811055

Group type: EXPERIMENTAL
Intervention: Tablet-based game (3 × 10 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 16
Study: 25086821

Group type: EXPERIMENTAL
Intervention: Combined internal and external fixation (CIEF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 44
Study: 22277140

Group type: EXPERIMENTAL
Intervention: Carvedilol controlled‐release plus lisinopril (C+L)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus lisinopril (H+L)
Number of subjects: 25
Study: 19169910

Group type: COMPARATOR
Intervention: Suction Cup (SC) method
Number of subjects: 36

Group type: COMPARATOR
Intervention: Soft Tissue Stiffness Meter (STSM) method
Number of subjects: 36
Study: 17559737

Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg once daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg once daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Co-administration of posaconazole and phenytoin (both 200 mg once daily)
Number of subjects: 36
Study: 16299322

Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (2 doses, 28 days apart)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (1 dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular injection of MCP-CRM197 conjugate vaccine in alum
Number of subjects: 36
Study: 11927206

Group type: EXPERIMENTAL
Intervention: High-risk ('selected') patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk-adjustment methodology
Number of subjects: 0
Study: 9628497

Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction of the ossicular chain
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction with stapes prosthesis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bone cement (Oto-Cem) reconstruction (incus to oval window repairs)
Number of subjects: 9
Study: 7697308

Group type: EXPERIMENTAL
Intervention: Active administration of specific bacterial cultures in fermented milk
Number of subjects: 40
Study: 30975673

Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring with study biopsy for subclinical rejection and treatment per protocol.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine post‐transplant monitoring (Control).
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Urine CXCL10 monitoring strategy.
Number of subjects: 250